echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Johnson & Johnson CD38 monoclonal antibody new indication approved in China, sales of 4.19 billion U.S. dollars in 2020

    Johnson & Johnson CD38 monoclonal antibody new indication approved in China, sales of 4.19 billion U.S. dollars in 2020

    • Last Update: 2021-05-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the official website of the State Food and Drug Administration showed that Xi’an Janssen’s application for new indications for Darzalex injection (Darzalex) in China (acceptance number: JXSS2000019/20) has been approved by the NMPA.


    Xi'an Janssen submitted a listing application for this indication to NMPA in April 2020, and was included in the priority review by CDE in October 2020.


    Multiple myeloma (MM) is an incurable hematological malignancy.


    CD38 is highly expressed in multiple myeloma cells.


    Daratumumab is the first fully human monoclonal antibody targeting CD38 approved globally and domestically.


    Medicine Rubik's Cube NextPharma

    Medicine Rubik's Cube NextPharma

    In addition, Xi'an Janssen submitted a listing application for Darzalex Faspro in China on November 6 last year.


    In addition, the clinical application of Fuhong Henlius daratumumab biosimilar drug was granted the default approval of CDE on January 12 this year.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.